Novartis Institutes for BioMedical Research.
Expert Opin Drug Discov. 2007 Feb;2(2):285-94. doi: 10.1517/17460441.2.2.285.
High-throughput screening of chemical libraries for compounds that interfere with a particular molecular target is among the most powerful methodologies applied in lead discovery at present. In this review, the authors describe a label-free, homogeneous, affinity-selection-based technology developed at Novartis, termed SpeedScreen, which is compared with similar technologies used for high-throughput screening in the pharmaceutical and biotechnology industries. The focus at present of SpeedScreen is twofold: first, this technology is applied to orphan genomic targets and to those targets that are non-tractable by a functional assay; second, this technology is applied complementary to the well-established traditional methodologies for the screening of molecular targets. In summary, the authors discuss the value of affinity-selection-based high-throughput screening as a complementary technology to the common functional screening platforms and the benefits as well as the limitations of this new technology are outlined.
高通量筛选化学文库中干扰特定分子靶标的化合物是目前在先导化合物发现中应用最广泛的方法之一。在这篇综述中，作者描述了一种由诺华公司开发的无标记、均相、基于亲和选择的技术，称为 SpeedScreen，并将其与制药和生物技术行业中用于高通量筛选的类似技术进行了比较。目前，SpeedScreen 的重点有两个方面：首先，该技术应用于孤儿基因组靶标和那些无法通过功能测定的靶标；其次，该技术作为对成熟的传统分子靶标筛选方法的补充。总之，作者讨论了基于亲和选择的高通量筛选作为对常见功能筛选平台的补充技术的价值，以及概述了这项新技术的优势和局限性。
